SLC5A2 and coronary artery disorder: While the primary endpoint in these CVOTs has been 3-point MACE, reductions in nonfatal/fatal MI and attenuated ischemic heart disease do not appear to be the primary driver of improved cardiovascular outcomes for SGLT2 inhibitors, but may play a more important role for the improved cardiovascular outcomes with GLP-1R agonists.